As a massive Covid-19 surge continues to rage on throughout India, scientists and public health officials scramble to determine whether currently authorized vaccines in the country can provide a mitigation effect to this unprecedented spread. A new study published online has provided some hope, with researchers suggesting that the Covaxin vaccine – developed by Bharat Biotech and Pennsylvania-based Ocugen – could neutralize the SARS-CoV-2 variant leading the second wave in India.
AstraZeneca on April 26 said that legal action by the European Union against the pharmaceutical company over the supply of the company’s Covid-19 vaccine was without merit and pledged to defend itself strongly in court.
Children attending summer camp can get within 3 feet (1 meter) of each other but should wear masks to limit the spread of Covid-19, according to fresh guidance issued by the U.S. Centers for Disease Control and Prevention.
Researchers from Albert Einstein’s College of Medicine are excited with the recently published findings of an experimental drug that reversed key symptoms of Alzheimer’s disease in mice.
The U.S. Food and Drug Administration approved GlaxoSmithKline’s new checkpoint inhibitor, Jemperli (dostarlimab), for patients with recurrent or advanced endometrial cancer.
Microbial sciences company Seed Health closed a $40 million Series A financing round and Dutch company Anavo Therapeutics announced seed financing totaling €20 million ($24 million) to discover small molecules that target phosphatases.
The European Commission is working on legal proceedings against AstraZeneca after the drugmaker cut Covid-19 vaccine deliveries to the European Union, sources familiar with the matter said.
In a move to help underserved women join the workforce and to strengthen the impact of its employee volunteer efforts, The Bloc joined the business community of Working for Women (W4W).
Roche culled two more Phase II Covid-19 programs, as announced in the Swiss pharma giant’s first-quarter 2021 financial report.
Johnson & Johnson is establishing a vaccine supply network in which 10 manufacturing sites would be involved in the production of the company’s Covid-19 vaccine, in addition to J&J’s plant in Leiden, the Netherlands.
